The Biotechnology Innovation Machine: A Source of Intelligent Biopharmaceuticals for the Pharma Industry—Mapping Biotechnology’s Success
Authors:
- 21 January 2014
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 95 (5) , 528-532
Abstract
The marriage of biotechnology and the pharmaceutical industry (pharma) is predicated on an evolution in technology and product innovation. It has come as a result of advances in both the science and the business practices of the biotechnology sector in the past 30 years. Biotechnology products can be thought of as "intelligent pharmaceuticals," in that they often provide novel mechanisms of action, new approaches to disease control, higher clinical success rates, improved patient care, extended patent protection, and a significant likelihood of reimbursement. Although the first biotechnology product, insulin, was approved just 32 years ago in 1982, today there are more than 200 biotechnology products commercially available. Research has expanded to include more than 900 biotechnology products in clinical trials. Pharma is substantially engaged in both the clinical development of these products and their commercialization.Keywords
This publication has 5 references indexed in Scilit:
- Inside Industry2012
- What's fueling the biotech engine—2009–2010Nature Biotechnology, 2010
- Biopharmaceutical benchmarks 2010Nature Biotechnology, 2010
- Public biotech 2009—the numbersNature Biotechnology, 2010
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology & Therapeutics, 2010